Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
12actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-12 | actual | When the study began enrolling |
| Primary completion | 2026-07-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-17 | actual | The whole study's end, after follow-up |
| First posted | 2026-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Intervention
- Drug: Emraclidine
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured Up to approximately 44 days
Maximum Observed Plasma Concentration (Cmax) of Emraclidine
measured Up to approximately 14 days
Time to Cmax (Tmax) of Emraclidine
measured Up to approximately 14 days
Area Under the Concentration-Time Curve from Time 0 to Time t (AUC) of Emraclidine
measured Up to approximately 14 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed